Ashwin Gollerkeri

As Senior Vice President, Head of Development at Kymera Therapeutics, Ashwin is responsible for all phases of Kymera’s drug development programs. Ashwin offers more than 20 years of drug development experience, including service at Pfizer Inc., Array BioPharma, Novartis AG, and Bristol-Myers Squibb Company (BMS). As Vice President of Clinical Science-Oncology at Array, Ashwin’s efforts led to successful filings of New Drug Applications for the targeted cancer therapies BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib). Ashwn has also held various leadership roles in clinical development and research at Pfizer, Novartis, and BMS. Ashwin holds a BA degree in Cell and Developmental Biology from Northwestern University and an MD from the University of Kansas School of Medicine. Ashwin subsequently trained in Internal Medicine and completed a Chief Residency at The Miriam Hospital-Brown University School of Medicine and in Medical Oncology at Yale University School of Medicine.